BioMark Diagnostics Profit Margin

BioMark Diagnostics (BUX.CN) currently reports a profit margin of -5127.11% as of June 2026. That compares with -1110.44% in the prior-year period — down 361.7% year over year. That is below the sector sector average of 13.23%. Use the charts on this page to explore BioMark Diagnostics's profit margin history and peer comparisons.

BioMark Diagnostics's profit margin decreased from -1110.44% to -5127.11% — a 361.7% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

BioMark Diagnostics's profit margin of -5127.11% is lower than the its sector sector average of 13.23%. That is roughly 38865.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but BioMark Diagnostics's current -5127.11% should be judged against industry norms (sector average: 13.23%) and against BUX.CN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -5127.11%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 13.23%. From there, open related valuation or income-statement pages for BioMark Diagnostics, and consider following BUX.CN for alerts when major investors trade the stock.